Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular Vesicles as Orchestrators of Osteoimmunomodulation in Peri-Implantitis: Implications for Bone Regeneration

Bonilla M., Carretero-Fernández M., Sainz J., Mesa F.

Narrative Review on Immune Modulation, published in Clin Implant Dent Relat Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Clin Implant Dent Relat Res (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42021463
PMCID
PMC13103432
DOI
10.1111/cid.70151
Citations
1

Abstract (original English)

Introduction Peri-implantitis, characterized by inflammatory bone loss, is a leading cause of dental implant failure. Current regenerative strategies face limitations due to the persistent inflammatory microenvironment. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising acellular therapeutics with dual osteogenic and immunomodulatory capacities, offering a novel approach to address the complexity of peri-implant bone defects. Methods This narrative review synthesizes preclinical evidence on MSC-EVs for peri-implant bone regeneration. It examines methods for EV isolation from various sources. Furthermore, it analyzes advanced engineered delivery systems, such as peptide-functionalized implant surfaces and bioactive scaffolds, designed to enhance local retention and therapeutic efficacy. Results MSC-EVs orchestrate bone regeneration through multifaceted mechanisms. They directly stimulate osteogenesis by transferring pro-osteogenic miRNAs and proteins, activating key pathways like PI3K/AKT and Wnt/β-catenin. Crucially, they modulate the osteoimmune environment by reprogramming macrophages toward a reparative M2 phenotype, suppressing pro-inflammatory Th1/Th17 responses, and expanding regulatory T cells (Tregs). Concurrently, MSC-EVs inhibit bone resorption by favorably modulating the RANKL/OPG balance and directly interfering with osteoclast

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansBone RegenerationOsteogenesisPeri-ImplantitisExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research